動脈硬化症におけるDNAメチル化によるモノカルボキシラートトランスポーターMCT3の不活性化
Shoukang Zhu1, Pascal J Goldschmidt-Clermont, Chunming Dong
1Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Circulation
|August 24, 2005
まとめ
DNAメチル化は,滑らかな筋肉細胞 (SMC) でのモノカルボキシラートトランスポーター3 (MCT3) 発現を抑制し,乳酸輸送を阻害する. この表遺伝的調節は,SMCの増殖と動脈硬化症の発達に関連しています.
科学分野:
- 細胞生物学 細胞生物学
- エピジェネティクス エピジェネティクス
- 心血管研究に関する研究.
背景:
- モノカルボキシラートトランスポーター (MCT) は,細胞のエネルギー代謝に不可欠な乳酸の輸送を促進します.
- 滑らかな筋肉細胞 (SMC) のMCTを調節するメカニズムは十分に理解されていません.
- 乳酸輸送は,動脈硬化症のような心血管疾患に関与しています.
研究 の 目的:
- SMCにおけるMCT発現と機能に対するDNAメチル化の影響を調査する.
- SMCフェノタイプと動脈硬化症におけるMCTの役割を決定する.
- SMCにおけるモノカルボキシラート輸送のエピジェネティック・レギュレーションを解明する.
主な方法:
- リアルタイムRT-PCR,ウェスタン・ブロッティング,およびMCT発現分析のための免疫ヒスト化学.
- SMCにおけるDNAメチル化パターンを評価するためのビスルファイト配列解析.
- 乳酸輸送の可視化と機能的測定のためのコンフォカル顕微鏡.
主要な成果:
- 増殖するSMCで観察されたMCT3のダウンレギュレーションと乳酸輸送の減少.
- 経路数と動脈硬化病変の進行は,MCT3プロモーターメチル化と相関しています.
- デメチル化治療により,MCT3発現が回復し,乳酸輸送が正常化しました.
- MCT3のノックダウンは,SMCの拡散を促進しました.
結論:
- DNAメチレーションは,SMCにおけるMCT3発現をエピジェネティックに調節する.
- メチル化によるMCT3発現抑制は乳酸輸送を阻害し,SMCの増殖を誘発する可能性がある.
- このメカニズムは,動脈硬化症の病原化に寄与する可能性があります.
関連する概念動画
Epigenetic Regulation
34.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.4K
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Epigenetic Regulation
4.2K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
4.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets
88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
Atherosclerosis III: Management
593
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
593


